


Practical Implementation of the Lifecycle Approach to Process Validation





GOOD PRACTICE GUIDE:

Practical Implementation of the Lifecycle Approach to Process Validation

Disclaimer:

This *ISPE Good Practice Guide: Practical Implementation of the Lifecycle Approach to Process Validation* provides detailed practical guidance to help pharmaceutical companies meet global regulatory process validation expectations. This Guide is solely created and owned by ISPE. It is not a regulation, standard or regulatory guideline document. ISPE cannot ensure and does not warrant that a system managed in accordance with this Guide will be acceptable to regulatory authorities. Further, this Guide does not replace the need for hiring professional engineers or technicians.

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, or the authors, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© Copyright ISPE 2019. All rights reserved.

All rights reserved. No part of this document may be reproduced or copied in any form or by any means – graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems – without written permission of ISPE.

All trademarks used are acknowledged.

ISBN 978-1-946964-18-2

Foreword

During my tenure at the FDA, I presented at many industry conferences on various topics, but few represented such significant change and improvement as those which culminated in the lifecycle approach to Process Validation (PV). In 2002, FDA launched the Pharmaceutical Quality for the 21st Century initiative aimed at modernizing pharmaceutical manufacturing using sound science and risk-based approaches. ICH shortly thereafter also embarked on its vision for pharmaceutical quality and set forth ICH Q8, Q9, Q10, and Q11.

- Q8 Pharmaceutical Development (August 2009)
- Q9 Quality Risk Management (November 2009)
- Q10 Pharmaceutical Quality System (June 2008)
- Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (May 2012)

A fundamental principle to ensure product quality is PV. In the past, interpretation of FDA's Compliance Policy Guide (<http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074411.htm>), which addressed process validation and the subject of guidance from FDA over multiple versions, there had been the impression that three commercial PV batches were almost always enough to ensure a robust and consistent process. This guide was updated in 2004 to facilitate understanding of requirements to bring products to market, especially when extensive process development efforts and large numbers of PV batches are not practical, e.g., orphan drugs.

Over time in FDA and in other international guidances, three batches had become the standard to demonstrate a validated process. With the lifecycle approach, efforts were made to bring PV into the 21st Century - to provide scientific evidence to justify going from development to commercial manufacturing while maintaining the desired process control over the product's lifecycle. The intent was also to capture modern manufacturing methods using enhanced approaches, e.g., continuous manufacturing.

In 2011, the 1987 Guideline on General Principles of Process Validation was replaced, reflecting the modernization efforts for pharmaceutical quality initiated by FDA and in the international arena. Of the regulatory guidances issued to date, the FDA Guidance for Industry: Process Validation: General Principles and Practices of January 2011 contains the most detail in regard to expectations for the three stages of the lifecycle approach to PV, but was followed internationally by several other impactful guidances and regulations, outlined below.

In February 2014, EMA published its "Guideline on process validation for finished products – information and data to be provided in regulatory submissions." The scope of this document covered:

- Human medicinal products
- Veterinary medicinal products
- Biological products

A companion guideline "Guideline on process validation for the manufacture of biotechnology-derived active substances and data for inclusion in the regulatory submission" was published in April 2014.

These documents introduced the concepts of science and risk-based validation to Europe via:

- Process evaluation (Stages 1 and 2)
- Process verification (Stage 3)

The EU PV guidance sets out three approaches for PV:

- Traditional (three batches)
- Continuous process verification
- Hybrid (three batches or Continuous in different steps of the process)

Additionally, these guidance documents refer to GMP requirements for PV in Annex 15: Qualification and Validation to the EudraLex Volume 4 (Good Manufacturing Practice Medicinal Products for Human and Veterinary Use). This guidance was published for comment in March 2015 and became operational in October of the same year concurrent with its publication by PIC/S. Unlike the FDA guidance; Annex 15 also contains specific validation approaches to:

- Transport verification
- Packaging qualification
- Utilities qualification
- Test method validation
- Cleaning validation

The EMA guideline on PV for finished products underwent a minor update in November 2016.

With these modern approaches to pharmaceutical development and manufacturing and the advancement of the concept of PV to a lifecycle approach, ISPE's Product Quality Lifecycle Initiative (PQLI[®]) has been providing the technical underpinnings to develop the necessary education, training, and discussion papers to pharmaceutical professionals engaged in all facets of pharmaceutical development, commercialization, and manufacturing. This *Good Practice Guide: Practical Implementation of the Lifecycle Approach to Process Validation* brings together an excellent reference providing the technical and scientific detail needed to lead PV through scientifically sound development to robust reliable processes, ensuring the continued supply of quality medicines to patients.

An expert group of volunteers with manufacturing, quality, technical development, and statistician backgrounds has brought this effort to the point of providing this Guide to our ISPE members. It covers a wide variety of manufacturing types including small and large molecule, active pharmaceutical ingredients (including intermediate steps), solid oral dosage forms, sterile drug product, etc.

This Guide will be an invaluable reference bringing together many of the efforts to date for use in your daily activities and as an underpinning to ISPE's ongoing education and training in this area.

Joe Famulare

Former FDA Deputy Director, Office of Compliance, CDER

Vice President, Compliance and External Collaboration, Genentech, A Member of the Roche Group

Past Chair, ISPE International Board of Directors



600 N. Westshore Blvd., Suite 900, Tampa, Florida 33609 USA
Tel: +1-813-960-2105, Fax: +1-813-264-2816

www.ISPE.org

Acknowledgements

The Guide was produced by a Task Team led by Dilip Ayyala Somayajula (Boehringer Ingelheim, USA) and Robert Beall, PMP (ProPharma Group, USA). The work was supported by the ISPE Process Validation Team.

Core Team

The following individuals took lead roles in the preparation of this Guide:

Joanne Barrick*	Eli Lilly & Co.	USA
James Bergum*	BergumSTATS, LLC	USA
Christopher C. Breen	Eli Lilly & Co.	USA
Paul Corbishley	AstraZeneca	United Kingdom
Mette Kraemmer Hansen	Novo Nordisk A/S	Denmark
Canping Jiang	Biogen	USA
Line Lundsberg-Nielsen	NNE	Denmark/United Kingdom
Matt McMenemy	GlaxoSmithKline	USA
Thomas Parks	Eli Lilly & Co.	USA
Maurice Parlane*	New Wayz Consulting Ltd./CBE Pty Ltd.	New Zealand
Pritesh Patel	Pritesh Patel Consulting, LLC	USA
Ajay Babu Pazhayattil	Eurofins Alphora Research Inc.	Canada
Lori B. Pfahler*	Merck & Co., Inc	USA
Tara Scherder*	SynoloStats	USA
Lauren Smith	Cook Pharmica	USA
Thomas Stepinac	Novartis Pharma Productions GmbH	Germany
Kim Vukovinsky*	Pfizer Inc.	USA
Jonathan Brett Wade	Eli Lilly & Co.	USA
Jenn Walsh*	Maia Pharmaceuticals	USA
Fred Wiles	ProPharma Group	USA

*These individuals went above and beyond expectations to meet deadlines and keep the effort on track.

Contributors and Team Reviewers

The Leads wish to thank the following individuals for their valuable contribution during the preparation of this Guide.

Daniel Alsmeyer	Impax Laboratories Inc.	USA
Kurtis Epp	CSL Behring AG	Switzerland
Joe Famulare	Genentech/Roche	USA
Gary Gamboa	Eli Lilly & Co., (retired)	USA

Regulatory Input and Review

Particular thanks go to the following for their review and comments on this Guide:

Norman Gray	Medicines and Healthcare products Regulatory Agency (MHRA)	United Kingdom
-------------	--	----------------

Special Thanks

The Team would like to give particular thanks to James Bergum (BergumSTATS, LLC, USA) and Maurice Parlane (New Wayz Consulting Ltd./CBE Pty Ltd., New Zealand) for their tireless dedication to pulling this across the finish line. The Leads would like to thank Bruce Davis (Global Consulting, United Kingdom) for his efforts as ISPE Guidance Documents Committee (GDC) Mentor. The Team would also like to thank ISPE for technical writing and editing support by Jeanne Perez (ISPE Guidance Documents Technical Writer/Editor) and production support by Lynda Goldbach (ISPE Guidance Documents Manager).

The Team Leads would like to express their grateful thanks to the many individuals and companies from around the world who reviewed and provided comments during the preparation of this Guide; although they are too numerous to list here, their input is greatly appreciated. Company affiliations are as of the final draft of the Guide.

Cover photo: courtesy of Boehringer Ingelheim Fremont, Inc., www.boehringer-ingelheim.com

Table of Contents

1	Introduction	7
1.1	Foundation for the Good Practice Guide	8
1.2	Global Acceptance/Authorization	9
1.3	Scope.....	12
1.4	Purpose.....	12
1.5	Benefits	13
2	Basic Terms Used in the Process Validation Lifecycle.....	15
2.1	Process Validation Lifecycle Stages	15
2.2	Stage 1 Process Design/Pharmaceutical Development	16
2.3	Stage 2 Key Terms and Substages.....	17
2.4	Stage 3 Continued (Ongoing) Process Verification and Substages.....	18
2.5	Key Statistical Terms.....	19
3	Design Development Phase (Stage 1).....	21
3.1	Apply Statistics in PV Stage 1.....	22
3.2	Assess Variability in Stage 1	24
3.3	Leverage Stage 1 Data	28
3.4	Determine Design Space and Control Strategy.....	31
3.5	Validation Master Plan	44
3.6	Readiness for Stage 2 (Process Performance Qualification).....	45
4	Design and Qualification of Facility, Utilities, and Equipment (Stage 2.1)	49
4.1	Overview and Background.....	49
4.2	Review of Establishing Equipment Qualification Ranges	50
4.3	Impact of Product and Process on Facilities, Utilities, and Systems	50
5	Initial Process Qualification Activities (Stage 2.2)	53
5.1	Determine an Appropriate Number of Initial Process Validation Batches and Inter-Batch Variability Assessment.....	53
5.2	Determine Science and Statistically-Based Process Validation Acceptance Criteria and Sampling Plans ...	58
5.3	Process Validation (Process Performance Qualification) Acceptance Criteria	67
5.4	Stage 2.2 Process Review.....	73
6	Continued Process Verification (Stage 3)	77
6.1	Determine the Continued Process Verification Plan	77
6.2	Determine which Variability to Include in the Continued Process Verification Plan	79
6.3	Determining Statistically-based Routine Sampling and Testing for Continued Process Verification.....	82
6.4	Dissolution	91
6.5	Evaluate Legacy Products for Heightened Monitoring/Testing Need.....	93
6.6	Periodic Review and Revalidation	95
6.7	Report: Frequency, Recommendations for Further Actions, Relevance with Annual Product Review	97
7	Contract Manufacturing	99
7.1	Contract Development, Manufacturing, and Packaging Organizations and License Holder Relationship....	99
7.2	Maintaining Compliance while Ensuring Flexibility	99
7.3	Best Practices in Stage 1.....	99
7.4	Best Practices in Stage 2.....	101
7.5	Best Practices in Stage 3.....	102
7.6	Stage Gate Processes.....	102
7.7	Regulatory Audit Expectations.....	105
7.8	Contract Development, Manufacturing, and Packaging Organizations – Specialized versus One Source Models.....	105

8	Change Management	107
8.1	Change Management Principles.....	107
8.2	Changing Manufacturing Sites.....	109
9	Appendix 1 – Case Study: Legacy Products	111
9.1	Executive Summary.....	111
9.2	Case Study Overview and Background.....	111
9.3	Critical Quality Attributes Operating Characteristic Curves.....	114
9.4	Estimate the Number of Samples for the Process Validation Stage 2.2 Protocol.....	118
9.5	Assess Stage 2.2 Data.....	119
9.6	Product Risk Evaluation and Enhanced Controlled Strategy for Continued Process Verification (Stage 3.1).....	122
10	Appendix 2 – NDA Products Case Studies: Small Molecules	125
10.1	Case Study 1: Selection of CQAs and PPs for CPV – Applying Risk-based Approach to CPV Determination to a New Small Molecule Drug Product, Utilizing Data from the <i>ISPE PQLI® Guide Part 2 – Illustrative Example</i> [35].....	125
10.2	Case Study 2: Batch Size Reduction Process Performance Qualification.....	132
11	Appendix 3 – NDA Products Case Studies: Large Molecules or Bio-derived Products	143
11.1	Case Study 1: Large Molecule Example Column Chromatography Step – Parameter Selection for CPV [35].....	143
11.2	Case Study 2: Process Validation of a Cell Culture Product.....	149
12	Appendix 4 – Contract Manufacturing Product Case Studies	159
12.1	Case Study 1: Insufficient Information Transfer in Design.....	159
12.2	Case Study 2: Allowing Flexibility.....	160
13	Appendix 5 – Additional Information on Determining the Number of Process Performance Qualification Batches	161
13.1	Further Explanation of Risk Assessment in Preparation for Determining the Number of PPQ Batches [34].....	161
13.2	Determining the Number of PPQ Batches Based on a Risk-based Approach Utilizing the <i>ISPE PQLI® Guide Part 2 – Illustrative Example</i> [8] [34].....	165
14	Appendix 6 – Statistical Detail	173
14.1	Operating Characteristic Curves of Sampling Plans and Acceptance Criteria.....	173
14.2	k Value Approximation for Two-Sided Tolerance Interval.....	175
14.3	Generation of Acceptance Limit Table for Two-Sided Tolerance Interval Approach.....	175
14.4	OC Curves for USP UDU <905> Test [46] Based on 85% – 115% Coverage.....	176
14.5	“Exact” Method – Statistical Details.....	176
14.6	R Program to Generate Acceptance Limit Tables for the Exact Method.....	179
14.7	Approximation to Exact Acceptance Limits Using a Polygon.....	180
14.8	Graphical Comparison of Acceptance Limit Tables.....	182
14.9	Operating Characteristic Curves to Help Select Sampling Plan.....	183
14.10	Formula for Calculating the Tolerance Interval Endpoints [54].....	185
14.11	Dissolution Acceptance Limit Tables.....	186
15	Appendix 7 – References	191
16	Appendix 8 – Glossary	195
16.1	Acronyms and Abbreviations.....	195
16.2	Definitions.....	199

1 Introduction

Between 2004 and 2009, ICH published guidance documents Q8 (Quality by Design – Pharmaceutical Development) [1], and Q9 (Quality Risk Management) [2], which describe the science and risk-based approach to the development of pharmaceutical products. These guidances represented a paradigm shift in development, commercialization, transfer, and management throughout the product lifecycle.

The science and risk-based approach to Process Validation (PV) leverages information and knowledge from product development activities to make certain patient requirements are translated into product attributes. This requires that suitable manufacturing processes are defined with a control strategy that reliably ensures these attributes are met. Regulatory authorities worldwide have published revised guidances for science and risk-based approaches to be applied to PV, which presents a significant change to the way validation had been conducted.

PV demonstrates manufacturing control strategy adequacy and robustness and provides ongoing assurance that the process remains in control. It is defined in the 2011 FDA PV Guidance as [3]:

“...the collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product. Process validation involves a series of activities taking place over the lifecycle of the product and process.”

Other regulatory authorities have similar definitions for PV although terminology may differ.

This new (enhanced) approach to PV encompasses three stages, illustrated in Figure 1.1, as compared to the traditional or historic approach. The science and risk-based approach combines product development knowledge with a structured process performance and product quality monitoring system to provide for validation throughout the product lifecycle.

Figure 1.1: Process Validation Overview – Process Validation Lifecycle – the Enhanced Approach

